PACIFIC BIOSCIENCES OF CALIFORNIA INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
PACB$2.24-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · Additional Paid-inCapital · AccumulatedOtherComprehensive Income (Loss) · Accumulated Deficit · TotalStockholders'Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands) · Shares · Amount | ||||||
| Balance at December 31, 2020 | 192,294 | $192 | $1,372,083 | $85 | $(1,036,869) | $335,491 |
| Net loss | — | — | — | — | (181,223) | (181,223) |
| Other comprehensive loss | — | — | — | (1,172) | — | (1,172) |
| Issuance of common stock in conjunction with equity plans | 8,557 | 9 | 31,797 | — | — | 31,806 |
| Issuance of common stock in Private Placement, net of issuance costs | 11,215 | 11 | 294,834 | — | — | 294,845 |
| Issuance of common stock in acquisition of Omniome | 8,912 | 9 | 237,876 | — | — | 237,885 |
| Share-based compensation expense | — | — | 73,355 | — | — | 73,355 |
| Balance at December 31, 2021 | 220,978 | $221 | $2,009,945 | $(1,087) | $(1,218,092) | $790,987 |
| Net loss | — | — | — | — | (314,248) | (314,248) |
| Other comprehensive loss | — | — | — | (3,678) | — | (3,678) |
| Issuance of common stock in conjunction with equity plans | 5,527 | 6 | 11,224 | — | — | 11,230 |
| Share-based compensation expense | — | — | 78,613 | — | — | 78,613 |
| Balance at December 31, 2022 | 226,505 | $227 | $2,099,782 | $(4,765) | $(1,532,340) | $562,904 |
| Net loss | — | — | — | — | (306,735) | (306,735) |
| Other comprehensive income | — | — | — | 4,984 | — | 4,984 |
| Issuance of common stock following milestone achievement | 8,988 | 9 | 84,752 | — | — | 84,761 |
| Issuance of common stock in acquisition of Apton | 6,121 | 6 | 76,636 | — | — | 76,642 |
| Issuance of common stock in connection with Apton liquidity event bonus plan | 169 | — | 2,111 | — | — | 2,111 |
| Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs | 20,125 | 20 | 189,180 | — | — | 189,200 |
| Issuance of common stock in conjunction with equity plans | 5,836 | 6 | 15,313 | — | — | 15,319 |
| Share-based compensation expense | — | — | 72,118 | — | — | 72,118 |
| Balance at December 31, 2023 | 267,744 | $268 | $2,539,892 | $219 | $(1,839,075) | $701,304 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.